Guichet Emilande, Aghokeng Fobang Avelin, Eymard-Duvernay Sabrina, Vidal Nicole, Ayouba Ahidjo, Ngole E. M., Delaporte Eric, Ciaffi L., Peeters Martine. (2016). Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon. Journal of Virological Methods, 237, p. 121-126. ISSN 0166-0934.
Titre du document
Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon
Guichet Emilande, Aghokeng Fobang Avelin, Eymard-Duvernay Sabrina, Vidal Nicole, Ayouba Ahidjo, Ngole E. M., Delaporte Eric, Ciaffi L., Peeters Martine
Source
Journal of Virological Methods, 2016,
237, p. 121-126 ISSN 0166-0934
With the increasing demand of HIV viral load (VL) tests in resource-limited countries (RLCs) there is a need for assays at affordable cost and able to quantify all known HIV-1 variants. VLs obtained with a recently developed open and polyvalent universal HIV-1 /SIVcpz/SIVgor RT-qPCR were compared to Abbott RealTime HIV-1 assay in Cameroon. On 474 plasma samples, characterized by a wide range of VLs and a broad HIV-1 group M genetic diversity, 97.5% concordance was observed when using the lower detection limit of each assay. When using the threshold of 3.00 log(10) copies/mL, according to WHO guidelines to define virological failure (VF) in RLCs, the concordance was 94.7%, 360/474 versus 339/474 patients were identified with VF with the new assay and Abbott RealTime HIV-1, respectively. Higher VLs were measured with the new assay, +0.47 log(10) copies/mL (95% CI; 0.42-0.52) as shown with Bland-Altman analysis. Eleven samples from patients on VF with drug resistance were not detected by Abbott RealTime HIV-1 versus two only with the new assay. Overall, our study showed that the new assay can be easily implemented in a laboratory in RLCs with VL experience and showed good performance on a wide diversity of HIV-1 group M variants.
